P
ALLO icon

Pfizer’s Allogene Therapeutics ALLO Stock Holding History

Pfizer’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.9M Hold
22,032,040
– – 27.55% 1
2026
Q1 		$49.8M Hold
22,032,040
– – 20.85% 2
2025
Q4 		$30.2M Hold
22,032,040
– – 12.76% 5
2025
Q3 		$27.3M Hold
22,032,040
– – 6.25% 5
2025
Q2 		$24.9M Hold
22,032,040
– – 4.32% 4
2025
Q1 		$32.2M Hold
22,032,040
– – 6.42% 2
2024
Q4 		$46.9M Buy
+22,032,040
New +$54.3M 1.81% 4

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pfizer's ALLO Position: Q2 2026 in Review

Pfizer held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 22,032,040 shares worth $46.9M. The position accounts for 27.55% of the portfolio, ranked #1.

Pfizer first reported a position in ALLO in Q4 2024 and has held it in 7 quarters since. The position peaked at $49.8M in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Pfizer held 22,032,040 shares of Allogene Therapeutics worth $46.9M as of Q2 2026.
  • Pfizer left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up 27.55% of Pfizer's portfolio in Q2 2026, its #1 holding.
  • Pfizer first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Pfizer's Allogene Therapeutics position peaked at $49.8M in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Pfizer's 13F filing for Q2 2026, filed 13 Aug 2026.